Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Inducing translation

This article has been updated

The field of induced pluripotent stem cells is barely seven years old, but already three groups are close to launching clinical trials. Ken Garber looks into the prospects and perils.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 27 June 2013

    In the PDF and print versions of this article initially published, the source for the graphic was omitted. It should have read Liheng Wang, New York Stem Cell Foundation. The omission has been corrected in the online PDF.


  1. Lister, R. et al. Nature 471, 68–73 (2011).

    Article  CAS  Google Scholar 

  2. Mekhoubad, S. et al. Cell Stem Cell 10, 595–609 (2012).

    Article  CAS  Google Scholar 

  3. Pomp, O. et al. Cell Stem Cell 9, 156–165 (2011).

    Article  CAS  Google Scholar 

  4. Schwartz, S.D. et al. Lancet 379, 713–720 (2012).

    Article  CAS  Google Scholar 

  5. Vierbuchen, T. et al. Nature 463, 1035–1041 (2010).

    Article  CAS  Google Scholar 

  6. Ieda, M. et al. Cell 142, 375–386 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Garber, K. Inducing translation. Nat Biotechnol 31, 483–486 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research